These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 28167558)
41. An update on benznidazole for the treatment of patients with Chagas disease. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658 [TBL] [Abstract][Full Text] [Related]
42. Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier. de Moura Ferraz LR; Tabosa AÉGA; da Silva Nascimento DDS; Ferreira AS; Silva JYR; Junior SA; Rolim LA; Rolim-Neto PJ J Mater Sci Mater Med; 2021 May; 32(6):59. PubMed ID: 33999312 [TBL] [Abstract][Full Text] [Related]
43. Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease. Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Kelly JM Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082291 [TBL] [Abstract][Full Text] [Related]
44. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138 [TBL] [Abstract][Full Text] [Related]
46. Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions. Figueirêdo CBM; Nadvorny D; Vieira ACQM; Schver GCRM; Soares Sobrinho JL; Rolim Neto PJ; Lee PI; Soares MFR Eur J Pharm Sci; 2018 Jul; 119():208-218. PubMed ID: 29679707 [TBL] [Abstract][Full Text] [Related]
47. Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease. Wiens MO; Kanters S; Mills E; Peregrina Lucano AA; Gold S; Ayers D; Ferrero L; Krolewiecki A Antimicrob Agents Chemother; 2016 Dec; 60(12):7035-7042. PubMed ID: 27550362 [TBL] [Abstract][Full Text] [Related]
48. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II). Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788 [TBL] [Abstract][Full Text] [Related]
52. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease. Ghobadifar MA; Kalani N; Gitiforouz M; Mosallanejad Z Rev Soc Bras Med Trop; 2014; 47(5):669. PubMed ID: 25467275 [No Abstract] [Full Text] [Related]
53. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial. Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503 [TBL] [Abstract][Full Text] [Related]
54. Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites. Cruz-Zetina G; del Rio-Rodriguez R; Ramos-Ligonio A; López R; Monteon V Am J Trop Med Hyg; 2012 Oct; 87(4):671-4. PubMed ID: 22890036 [TBL] [Abstract][Full Text] [Related]
55. Tolerance of benznidazole in treatment of Chagas' disease in adults. Pinazo MJ; Muñoz J; Posada E; López-Chejade P; Gállego M; Ayala E; del Cacho E; Soy D; Gascon J Antimicrob Agents Chemother; 2010 Nov; 54(11):4896-9. PubMed ID: 20823286 [TBL] [Abstract][Full Text] [Related]
56. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease. Alvarez MG; Vigliano C; Lococo B; Petti M; Bertocchi G; Viotti R Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):636-8. PubMed ID: 22898619 [TBL] [Abstract][Full Text] [Related]
58. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV. Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197 [TBL] [Abstract][Full Text] [Related]
59. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection. Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142 [TBL] [Abstract][Full Text] [Related]
60. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. Bahia MT; Nascimento AF; Mazzeti AL; Marques LF; Gonçalves KR; Mota LW; Diniz Lde F; Caldas IS; Talvani A; Shackleford DM; Koltun M; Saunders J; White KL; Scandale I; Charman SA; Chatelain E Antimicrob Agents Chemother; 2014 Aug; 58(8):4362-70. PubMed ID: 24841257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]